North America Drug Delivery Market

The North America drug delivery market is expected to grow from US$ 9,74,639.53 million in 2023 to US$ 14,29,417.79 million by 2028. It is estimated to register a CAGR of 8.0% from 2023 to 2028.  

Rising Incidence of Chronic Diseases Fuel North America Drug Delivery Market

According to the Centers for Disease Control and Prevention (CDC), ~6 in 10 people in the US suffered from at least one chronic disease, while ~4 in 10 people had two or more chronic diseases as of 2019. Patients suffering from chronic medical conditions deteriorate with time, resulting in an enormous burden on patients' families and society. According to the projections of the American Cancer Society (ACS), the US is likely to record ~1,958,310 new cancer cases and 609,820 deaths in 2023. Diabetes is a life-threatening chronic disease with no specialized cure. All types of diabetes can lead to various complications in different body parts and increase the risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with this disease. Cases of diabetes have been increasing significantly across the globe. 

The increased prevalence of chronic diseases has promoted more intensive research and development (R&D) in drug delivery systems in the past few decades. The therapeutic efficacy of drugs used to treat chronic disease can be improved with optimal drug delivery systems, such as nanoparticles (e.g., ceramic, polymeric, and metallic), micelles, liposomes, and dendrimers. Administration of a drug with a drug delivery system can also help reduce systemic side effects of drugs. Various drug delivery vehicles have been introduced for a targeted and controlled delivery of therapeutics against a wide range of chronic diseases, such as diabetes, cancer, atherosclerosis, myocardial ischemia, asthma, pulmonary tuberculosis, Parkinson's, and Alzheimer's. An appropriate drug delivery system enhances the therapeutic efficacy of any drug by ensuring high drug bioavailability for a long duration. Targeted drug delivery systems (TDDS) release drugs in a controlled manner at a preselected site in a subject’s body. Nanotechnology-based delivery systems are making a significant impact on cancer treatment, and polymers play a key role in the development of these nanoparticulate carriers. In addition to the versatility of the administration route, a few of the noteworthy technological advantages of nanotherapeutic drug delivery systems (NDDS) are prolonged half-life, improved biodistribution, increased drug circulation time, controlled and sustained drug release, and elevated intercellular drug concentration.

Given the chronic nature of these conditions, patients with chronic diseases rely on continuous drug treatment, which is associated with an ongoing risk of side effects. Developing appropriate delivery systems for targeted drugs can promote the accumulation of targeted medicines in pathogenic lesions, reduce systemic side effects, and improve patient outcomes. Thus, the increasing incidences of chronic and lifestyle diseases bolster the growth of the North America drug delivery systems market.

North America Drug Delivery Market Overview

North America is the largest market for drug delivery, with the US holding the largest market share, followed by Canada. The market growth in North America is characterized by increased demand for rare disease medications from biopharmaceutical and biotechnology companies, the presence of key market players, and extensive R&D conducted by various academic and research institutes. In addition, extensive research in pharmaceutical and biotechnology companies is expected to support the growth of the drug delivery market in North America during the forecast period. 

 North America Drug Delivery Market Revenue and Forecast to 2028 (US$ Million)

North America Drug Delivery Market Segmentation

The North America drug delivery market is segmented on the basis of route of administration, distribution channel, end user, and country.

Based on route of administration, the North America drug delivery market is segmented into injectable drug delivery, oral drug delivery, transmucosal drug delivery, topical drug delivery, implantable drug delivery, and ocular drug delivery. The injectable drug delivery segment held the largest share of the North America drug delivery market in 2023.

Based on distribution channel, the North America drug delivery market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the North America drug delivery market in 2023.

Based on end user, the North America drug delivery market is segmented into hospitals and clinics, home care settings, and other end users. The hospitals and clinics segment held the largest share of the North America drug delivery market in 2023.

Based on country, the North America drug delivery market is segmented into the US, Canada, and Mexico. The US dominated the share of the North America drug delivery market in 2023.   

Bausch Health Companies Inc, Baxter International Inc., Becton Dickinson and Co, Boehringer Ingelheim International GmbH, Boston Scientific Corp, Gerresheimer AG, GlaxoSmithKline Plc, Johnson & Johnson, Kindeva Drug Delivery LP, Novartis AG, Novo Nordisk AS, Pfizer Inc, and Sever Pharma Solutions are the leading companies operating in the North America drug delivery market.    

North America Drug Delivery Market Strategic Insights

North America Drug Delivery Market Segmentation Analysis

North America Drug Delivery Market Report Highlights

North America Drug Delivery Report Scope

North America Drug Delivery Market Country and Regional Insights